学术周报 · IF≥10 或专科旗舰刊

胃肠外科领域文献阅读汇编

2026年第46周 (2026-11-13) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
收录论文
7
临床研究
3
基础研究
4
IF≥20
3
IF 10-20
1
子领域
4
期刊种类
5
数据日期
2026-11-13

★本周 Top 10 高影响力文献

#论文期刊IF
1Chromatin plasticity and lineage repurposing: When gastric identity turns acidic.Cancer cellIF 56.1
2Chromatin accessibility trajectories reveal pre-cancerous epigenetic priming and an acid-driven immu...Cancer cellIF 56.1
3Tumor Cells Hijack Coagulation Signaling to Enable Immune Escape and Metastatic Dissemination.Cancer researchIF 22.6
4Nivolumab and total neoadjuvant treatment for locally advanced rectal cancer: results of a phase II ...ESMO openIF 10.6
5Sociobehavioral Comorbidities and Outcomes After Colectomy in a National United States Veteran Cohor...Annals of surgeryIF 7.4
6Clinical impact of additional gastrectomy for endoscopic curability C-2 lesions after endoscopic sub...Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationIF 6.1
7Global population-based prevalence of genetic carriers of CDH1-associated hereditary diffuse gastric...Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationIF 6.1

Ŧ期刊分布统计

期刊篇数IF
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2IF 6.1
Cancer cell2IF 56.1
ESMO open1IF 10.6
Cancer research1IF 22.6
Annals of surgery1IF 7.4

1胃癌 (4篇)

基础研究 (4篇)

Cancer research IF 22.6 2026-11-09 PMID: 43002440
Lymph node metastasis (LNM) represents a pivotal event in cancer progression and a major determinant of response to immune checkpoint blockade (ICB). Elucidation of the molecular mechanisms linking metastatic dissemination to immune suppression could identify potential therapeutic targets to improve ICB efficacy. Here, we identified the coagulation initiator tissue factor (F3) as a central regulator bridging tumor metastasis and immune evasion in gastric cancer (GC). F3 was significantly upregulated in LNM-positive tumors and correlated with impaired ICB responsiveness and poor clinical outcome. Mechanistically, the intracellular domain of F3 directly bound eEF1A1 to promote STAT3 phosphorylation and induce CCL20 expression, which selectively recruited CCR6+ regulatory T cells (Tregs) to establish an immunosuppressive microenvironment. Disruption of this F3-eEF1A1-STAT3-CCL20 axis with the clinically approved compound olsalazine disodium served as a compelling preclinical proof-of-concept to potently suppress tumor growth, abrogate Treg infiltration, and restore ICB sensitivity, all without perturbing basal coagulation. These findings redefine F3 from a canonical coagulation initiator to a tumor-intrinsic immunomodulator and reveal a druggable vulnerability that uncouples its oncogenic signaling from hemostasis.
中文摘要:淋巴结转移是癌症进展中的关键事件,也是决定免疫检查点阻断疗效的主要因素。阐明连接转移扩散与免疫抑制的分子机制,可能发现改善免疫检查点阻断疗效的潜在治疗靶点。本研究在胃癌中鉴定出凝血启动因子组织因子作为连接肿瘤转移和免疫逃逸的核心调节因子。组织因子在淋巴结转移阳性肿瘤中显著上调,并与免疫检查点阻断反应受损及不良临床预后相关。在机制上,组织因子的胞内结构域直接结合延伸因子1A1以促进STAT3磷酸化并诱导CCL20表达,从而选择性招募CCR6阳性调节性T细胞以建立免疫抑制微环境。使用临床批准的药物柳氮磺吡啶钠破坏该F3-eEF1A1-STAT3-CCL20轴,在临床前概念验证中显示出强效抑制肿瘤生长、消除调节性T细胞浸润并恢复免疫检查点阻断敏感性的作用,且不影响基础凝血功能。这些发现将组织因子从经典的凝血启动因子重新定义为肿瘤内在的免疫调节因子,并揭示了一种可靶向的脆弱环节,使其致癌信号与止血功能解偶联。
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association IF 6.1 2026-11-09 PMID: 43002353
Hereditary diffuse gastric cancer (HDGC) is a rare autosomal dominant genetic disorder caused by loss-of-function mutations in the tumor suppressor gene CDH1. We aimed to estimate the carrier prevalence of HDGC-associated CDH1 variants across genetic ancestry groups using a large genomic database to identify potential disparities. We conducted a population-based cross-sectional analysis of 807,162 unrelated individuals in gnomAD v4.1 across diverse genetic ancestry groups. CDH1 variants were identified using two approaches: (1) pathogenic or likely pathogenic (P/LP) variants classified by ClinVar or ClinGen, and (2) additional rare variants predicted to be deleterious in silico, including nonsense, frameshift, deleterious in-frame indels, splice-disrupting, and supported missense variants. Carrier frequency was estimated from combined allele frequencies and stratified by genetic ancestry. Among 3,381 CDH1 variants, 137 met study criteria. 47 were classified as P/LP by ClinVar or ClinGen, and 90 additional variants were predicted to be deleterious in silico. Using curated P/LP variants, the overall estimated carrier frequency was 8.67 per 100,000 individuals, with the highest ancestry-specific estimate in non-Finnish Europeans at 10.0 per 100,000. No carriers were observed in Ashkenazi Jewish, Finnish, or Middle Eastern groups. Inclusion of in silico-predicted variants increased the estimated carrier frequency to 44.1 per 100,000, with the highest estimate in the Middle Eastern group at 165.0 per 100,000. HDGC-associated CDH1 variants may be more broadly distributed across populations than previously recognized. This genotype-first approach provides population-level carrier estimates independent of clinical ascertainment and highlights ancestry-related variation requiring further clinical and functional validation.
中文摘要:遗传性弥漫型胃癌是由抑癌基因CDH1的功能缺失突变引起的罕见常染色体显性遗传病。我们旨在利用大型基因组数据库估计不同遗传祖先群体中HDGC相关CDH1变异的携带者患病率,以识别潜在的差异。我们对gnomAD v4.1数据库中807,162名无亲缘关系的个体进行了基于人群的横断面分析,涵盖多种遗传祖先群体。CDH1变异通过两种方法鉴定:一是由ClinVar或ClinGen分类的致病性或可能致病性变异;二是通过计算机模拟预测具有有害性的额外罕见变异,包括无义、移码、有害的同框插入缺失、剪接破坏以及有支持的错义变异。携带者频率是根据合并等位基因频率估算并按遗传祖先分层的。在3,381个CDH1变异中,137个符合研究标准。其中47个被ClinVar或ClinGen分类为致病性或可能致病性,另有90个变异通过计算机模拟预测具有有害性。使用经过筛选的致病性或可能致病性变异,估计总体携带者频率为每10万人8.67例,非芬兰欧洲人的祖先特异性估计值最高,为每10万人10.0例。在阿什肯纳兹犹太人、芬兰或中东群体中未观察到携带者。纳入计算机模拟预测的变异后,估计携带者频率增加至每10万人44.1例,其中中东群体的估计值最高,为每10万人165.0例。HDGC相关CDH1变异在人群中的分布范围可能比先前认识到的更广泛。这种基因型优先的方法提供了独立于临床发现的人群水平携带者估计,并突出了需要进一步临床和功能验证的祖先相关变异。
Cancer cell IF 56.1 2026-11-09 PMID: 42843336
Chromatin dynamics shape gastric cancer at every stage. In this issue of Cancer Cell, Wang et al. uncover a premalignant chromatin state primed for oncogenic activation alongside a pseudo-gastric subtype that hijacks acid secretion to evade antitumor immunity, revealing gastric proton pumps as a potential therapeutic target.
中文摘要:染色质动态在胃癌发展的各个阶段塑造肿瘤特征。本期Cancer Cell杂志中,Wang等人揭示了一种为致癌激活做准备的癌前染色质状态,以及一种劫持酸分泌以逃避免疫抗肿瘤反应的假胃亚型,表明胃质子泵是潜在的治疗靶点。
Cancer cell IF 56.1 2026-11-09 PMID: 42838052
Chromatin remodeling is prominent in cancers, yet it remains obscure how chromatin dynamics underlies stepwise tumorigenesis and informs anti-cancer therapeutics. By decoding a large-scale chromatin accessibility atlas of 650 multistage samples from 439 patients, we delineate epigenetic switches spanning multistep gastric tumorigenesis. A cancer-resembling epigenetic priming state in intestinal metaplasia licenses subsequent tumor initiation. In advanced malignancies, inter-tumoral diversity stratifies three epigenomic subtypes. The proliferative and mesenchymal-inflammatory subtypes are sensitive to neoadjuvant immunotherapy, while the pseudo-gastric subtype is intrinsically drug resistant. Mechanistically, the refractory subtype is featured by a unique gastric lineage-mimicking phenotype, governed in part by FOSL2 to up-regulate H+/K+ ATPase transporters and sculpt an acidic milieu suppressing CD8+ T cells. Inhibition of this phenotype by either FOSL2 depletion or vonoprazan, a clinically available acid blocker, sensitizes immunotherapy. Collectively, these findings highlight that chromatin accessibility dynamics facilitates sequential tumorigenesis from gastric pre-cancer and defines subtypes exploitable to guide immunotherapy and overcome drug resistance.
中文摘要:染色质重塑在癌症中十分显著,但其动力学如何驱动逐步肿瘤发生并指导抗癌治疗仍不清楚。通过解码来自439名患者的650个多阶段样本的大规模染色质可及性图谱,我们描绘了跨越多步骤胃癌发生的表观遗传开关。肠化生中存在一种类癌表观遗传启动状态,为后续肿瘤起始提供了许可。在晚期恶性肿瘤中,瘤间多样性划分出三种表观基因组亚型。增殖性和间质炎症性亚型对新辅助免疫治疗敏感,而假胃亚型则具有内在的药物耐药性。机制上,该难治性亚型以独特的胃谱系模拟表型为特征,部分由FOSL2调控上调H+/K+ ATPase转运蛋白并塑造酸性微环境,从而抑制CD8+ T细胞。通过耗竭FOSL2或使用临床可用的酸抑制剂vonoprazan抑制该表型,可增敏免疫治疗。综上所述,这些发现表明染色质可及性动力学促进了从胃癌前病变到肿瘤的连续发生过程,并定义了可用于指导免疫治疗和克服耐药性的亚型。

2胃癌/胃切除 (1篇)

临床研究 (1篇)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association IF 6.1 2026-11-10 PMID: 43007586
Endoscopic curability C-2 (eCura C-2) after gastric endoscopic submucosal dissection (ESD) carries a residual risk of lymph node metastasis (LNM), and additional gastrectomy is recommended. However, in older patients, its clinical impact on gastric cancer-specific death is uncertain because non-cancer mortality is common. We retrospectively reviewed 6,777 patients who underwent gastric ESD from July 2005 to December 2023 and identified those with eCura C-2. The primary analysis included patients aged ≥ 75 years (n = 215): an additional gastrectomy group (n = 151) and an observation group (n = 64). Overall survival was evaluated using the Kaplan-Meier method, and gastric cancer-specific death using competing-risk regression (Fine-Gray model), treating other-cause death as a competing event. Observed overall survival was higher in the surgery group (P < 0.001). However, gastric cancer-specific death was infrequent, with 60-month cumulative incidences of 3.8% (surgery) and 3.9% (observation); the association was estimated with substantial imprecision (sHR 0.95, 95% CI 0.19-4.88; P = 0.95). In contrast, other-cause death was significantly less frequent with surgery (sHR 0.27, 95% CI 0.17-0.43; P < 0.001). Findings were consistent in a landmark analysis (n = 208). LNM was confirmed in 9.3% (14/151) of surgery patients, and gastric cancer-specific death occurred in 3.3% (5/151). In this cohort of patients aged ≥ 75 years with eCura C-2 lesions, gastric cancer-specific death was uncommon, and its association with additional gastrectomy was imprecisely estimated; this does not indicate equivalent oncological outcomes. The marked difference in other-cause mortality suggested substantial treatment selection. These findings support individualized management in older patients.
中文摘要:经内镜黏膜下剥离术(ESD)后诊断为内镜治愈C-2(eCura C-2)的胃癌患者存在淋巴结转移风险,通常建议行追加胃切除术。然而,在老年患者中,由于非癌症死亡率较高,追加胃切除对胃癌特异性死亡的影响尚不明确。本研究回顾性分析了2005年7月至2023年12月期间接受胃ESD治疗的6,777名患者,并筛选出eCura C-2患者。主要分析纳入年龄≥75岁的患者(n=215),分为追加胃切除组(n=151)和观察组(n=64)。采用Kaplan-Meier法评估总生存率,并使用竞争风险回归模型(Fine-Gray模型)评估胃癌特异性死亡,将其他原因死亡视为竞争事件。结果显示手术组的总生存率更高(P<0.001)。然而,胃癌特异性死亡发生率低,5年累积发生率分别为手术组3.8%和观察组3.9%,其关联估计存在较大不精确性(sHR 0.95, 95% CI 0.19-4.88; P=0.95)。相比之下,手术组的非癌症死亡显著减少(sHR 0.27, 95% CI 0.17-0.43; P<0.001)。地标分析结果一致(n=208)。在手术组患者中,9.3%(14/151)确诊淋巴结转移,胃癌特异性死亡发生率为3.3%(5/151)。在该≥75岁eCura C-2病变患者队列中,胃癌特异性死亡并不常见,且其与追加胃切除的关联估计不精确;这并不能表明肿瘤学结局等效。非癌症死亡率的显著差异提示存在明显的治疗选择偏倚。这些发现支持对老年患者采取个体化管理策略。

3直肠癌/TME (1篇)

临床研究 (1篇)

ESMO open IF 10.6 2026-11-11 PMID: 43014085
CA209-8M4 is a prospective phase II trial evaluating the addition of nivolumab to total neoadjuvant treatment (TNT) in patients with locally advanced rectal cancer (LARC). Patients with LARC (T3-4Nany or TanyN1) up to 12 cm from the anal verge received standard chemoradiation (CRT) followed by chemoimmunotherapy (CIMT): six cycles of standard mFOLFOX6 and nivolumab at 240 mg. We defined a novel primary endpoint, combining pathological complete response (pCR) rate among operated patients and long-term (≥12 months) clinical complete response (cCR) rate for those electing watchful waiting, into a composite endpoint of modified pCR (mpCR) rate. Between April 2019 and March 2024, 29 patients were enrolled, median age 53 years, 72.4% male; 96.6% of tumors were cT3 or cT4, 69.0% cN+, and 96.6% microsatellite stable. Median distance from the anal verge was 7 cm; 51.7% of patients had grade ≥3 adverse events (AEs) during CIMT, including one fatality (mesenteric inflammation), attributed most likely to CRT's unresolved toxicity. Immune-mediated AEs occurred in four patients (13.8%): grade 3 diabetes mellitus (1) and grade 1 hepatitis (3), including one with asymptomatic hyper/hypothyroidism. Twenty-eight patients (96.6%) are assessable for mpCR: 6 of the 15 operated achieved pCR, and 13 were not operated with cCR ≥12 months, leading to a 67.9% mpCR rate. With a median follow-up of 43.5 months (range 25.0-84.1+), all 28 assessable pts are alive with no evidence of disease. The estimated 3-year disease-free survival and 5-year overall survival rates of the entire group are 93% [95% confidence interval (CI) 84-100] and 97% (95% CI 90-100), respectively. The addition of nivolumab to standard TNT in LARC seems safe and may enhance its effectiveness, with encouraging mpCR and survival rates. A multicenter randomized trial, further evaluating this strategy, is ongoing.
中文摘要:CA209-8M4是一项前瞻性II期试验,旨在评估在局部晚期直肠癌患者中将纳武利尤单抗加入总新辅助治疗的效果。入组患者为距肛缘12厘米以内的局部晚期直肠癌(T3-4N任何或T任何N1),接受标准放化疗后联合化学免疫治疗:六个周期的标准mFOLFOX6和240毫克纳武利尤单抗。我们定义了一个新的主要终点,将手术患者的病理完全缓解率与选择等待观察者的长期(≥12个月)临床完全缓解率结合,形成改良的病理完全缓解率复合终点。2019年4月至2024年3月期间,入组29名患者,中位年龄53岁,男性占72.4%;96.6%的肿瘤为cT3或cT4期,69.0%为cN+,96.6%为微卫星稳定。距肛缘的中位距离为7厘米;化学免疫治疗期间51.7%的患者出现≥3级不良事件,包括一例死亡(肠系膜炎症),最可能归因于放化疗未解决的毒性。免疫介导的不良事件发生在4名患者中(13.8%):3级糖尿病1例和1级肝炎3例,其中包括一名无症状的高/甲状腺功能减退症患者。28名患者(96.6%)可评估改良病理完全缓解率:15名手术患者中有6名达到病理完全缓解,13名未手术患者达到≥12个月的临床完全缓解,改良病理完全缓解率为67.9%。中位随访时间为43.5个月(范围25.0-84.1+),所有28名可评估患者均存活且无疾病证据。全组的估计3年无病生存率和5年总生存率分别为93% [95%置信区间(CI)84-100]和97%(95% CI 90-100)。在局部晚期直肠癌中将纳武利尤单抗加入标准总新辅助治疗似乎是安全的,并可能提高其有效性,改良病理完全缓解率和生存率令人鼓舞。一项进一步评估该策略的多中心随机试验正在进行中。

4结直肠切除 (1篇)

临床研究 (1篇)

Annals of surgery IF 7.4 2026-11-09 PMID: 43001819
To evaluate the independent association between sociobehavioral comorbidities (SBCs) and complications after colectomies in a national Veteran cohort. SBCs are determinants of health outcomes, and Veterans represent a high-vulnerability population. However, the relationship of SBCs with postoperative complications remains understudied, and current surgical risk models underestimate risk among patients with significant SBC burden. We conducted an observational study of Veterans undergoing elective colectomy included in the Veterans Affairs Surgical Quality Improvement Program (VASQIP). Structured data from the Veteran Health Administration Corporate Data Warehouse were used to identify 6 SBC phenotypes (mental health disorder, suicide risk, substance use, social isolation, housing instability, and food insecurity) across 3 preoperative ascertainment windows: ≤90 days, ≤365 days, and lifetime. The outcome was any 30-day VASQIP-defined postoperative complication. Multilevel logistic regression estimated associations between SBCs and complications. Among 38,188 Veterans undergoing colectomy between 2009 and 2025, the median age was 66 years; 5% were female; 30% were non-white; and 48% had cancer. Mental health disorder, social isolation, or substance use were each associated with an 8%-40% increase in the odds of a complication across all ascertainment windows. Within the most proximal window, risk of complication increased as SBC burden increased: 16% increased odds with 1 SBC (aOR 1.16, 95% CI: 1.09-1.23) and 80% increased odds with 4-6 SBCs (aOR 1.80, 95% CI: 1.32-2.36). In a national Veteran cohort, SBCs were associated with postoperative colectomy complications. The strongest associations were observed with SBCs ascertained within the 90-day window, and the odds increased in a dose-response relationship with increasing SBC burden.
中文摘要:本研究旨在评估社会行为共病(SBCs)与退伍军人队列结肠切除术后的并发症之间的独立关联。SBCs是影响健康结局的决定因素,而退伍军人属于高脆弱人群。然而,SBCs与术后并发症之间的关系研究不足,且现有的手术风险模型低估了具有显著SBC负担患者的风险。我们开展了一项观察性研究,纳入美国退伍军人事务部外科质量改进计划(VASQIP)中接受择期结肠切除术的退伍军人数据。利用退伍军人健康管理局企业数据仓库的结构化数据,我们在三个术前确认窗口(≤90天、≤365天和终身)识别出6种SBC表型(精神障碍、自杀风险、物质使用、社会隔离、住房不稳定和食物不安全)。结局指标为任何VASQIP定义的30天内术后并发症。采用多层逻辑回归估计SBCs与并发症之间的关联。在2009年至2025年间接受结肠切除术的38188名退伍军人中,中位年龄为66岁;女性占5%;非白人占30%;癌症患者占48%。在所有确认窗口中,精神障碍、社会隔离或物质使用均使并发症的发生几率增加8%-40%。在最接近的时间窗口内,随着SBC负担的增加,并发症风险也随之上升:1种SBC时几率增加16%(aOR 1.16, 95% CI: 1.09-1.23),4-6种SBC时几率增加80%(aOR 1.80, 95% CI: 1.32-2.36)。在全国退伍军人队列中,SBCs与结肠切除术后并发症相关。最强的关联出现在90天窗口内确认的SBCs,且几率随SBC负担增加呈剂量反应关系上升。